A field notebook on the trials
Semaglutide cut major cardiovascular events by a fifth in people with heart disease — here is the trial record that measured it.
An observational reading of the cardiovascular and metabolic literature on a once-weekly GLP-1 receptor agonist, with every hazard ratio and percentage logged to its study.
Start here
Semaglutide is a once-weekly (or once-daily, by mouth) medicine in a family called GLP-1 receptor agonists — drugs that copy a gut hormone the body makes after a meal. It is an approved prescription medicine for type 2 diabetes, for long-term weight management, for lowering the risk of heart attack and stroke in people who already have heart disease, and, since 2025, for a serious fatty-liver condition. People take it to steady blood sugar, to eat less and lose weight, and to protect the heart. In large trials it lowered weight, improved blood sugar, and cut the rate of serious heart events. The trade-off shows up mostly in the gut: nausea, and other stomach complaints, especially in the first weeks. This site reads the studies like a naturalist reads a habitat — slowly, in order, noting what was actually seen — and what people report, including the downsides, is gathered on the effects page.
What the trial record shows
Across the largest trials, the cardiovascular signal is the one that stands out. In SELECT, a trial of 17,604 adults who had heart disease and carried extra weight but did not have diabetes, once-weekly semaglutide 2.4 mg lowered the combined rate of cardiovascular death, nonfatal heart attack and nonfatal stroke by 20% versus placebo (hazard ratio 0.80; 95% CI 0.72-0.90) [3]. A hazard ratio (a number comparing how fast events pile up in two groups) below 1 means fewer events on the drug.
The finding was not new in 2023; it had a long root. In SUSTAIN-6, a 2016 trial in 3,297 people with type 2 diabetes at high cardiovascular risk, semaglutide cut that same three-part endpoint by about a quarter (HR 0.74; 95% CI 0.58-0.95) — though in that population rates of diabetic-eye complications were higher (HR 1.76; 95% CI 1.11-2.78) [2]. The oral form carried the pattern too: in PIONEER 6, once-daily oral semaglutide was no worse than placebo for major cardiovascular events, with a numerically lower event rate [8].
Weight came down hard in parallel. In the STEP 1 trial, once-weekly semaglutide 2.4 mg produced a mean body-weight change of -14.9% over 68 weeks, against -2.4% on placebo [1]. The same program logged broad improvements in cardiometabolic markers — waist size, blood pressure, lipids, glucose, inflammation [10].
A peptide built to last a week
Semaglutide is a semaglutide peptide — a 31-amino-acid chain modeled on the human gut hormone GLP-1, sharing about 94% of its sequence. Two changes make it endure. A swapped amino acid at position 8 blocks the enzyme DPP-4 (the body's main GLP-1 shredder) from cutting it, and a fatty-acid tail clipped to the chain binds tightly but reversibly to albumin, the most common protein in blood. Riding on albumin, the molecule is shielded from the kidneys and clears slowly, with an elimination half-life of about one week [17]. Native GLP-1 lasts roughly two minutes; this lasts seven days. That single engineering choice is why one injection covers a week.
The mechanism reaches the brain. In rodents, semaglutide entered the brainstem and the hypothalamus directly, switching on the satiety-signaling neurons and quieting the hunger-signaling ones, which lowered food intake and shifted food preference without slowing the burn of energy [4]. The full account is on the how-it-works page.
What this notebook is
This is an independent editorial digest. It does not sell semaglutide, does not prescribe it, and is not a clinic. It records what the peer-reviewed trials measured and what the research-use community reports, and it points you to the primary sources so you can read them yourself. Every quantitative claim here — every hazard ratio, every percentage, every n-value — is tied to a numbered citation you can follow on the Semaglutide references page.
If you want the human texture — the appetite that goes quiet, the sulfur burps, the nausea that peaks during titration — the Semaglutide effects page gathers the reported benefits and side effects, labeled plainly as anecdote, alongside the cited safety cautions. The kidney, liver, and head-to-head comparison data live in the research notes.